Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles

Jung Seok Kim,1,* Min Woo Kim,1,* Seong Jae Kang,1,* Hwa Yeon Jeong,1 Sang Il Park,1 Yeon Kyung Lee,1 Hong Sung Kim,2 Keun Sik Kim,3 Yong Serk Park1 1Department of Biomedical Laboratory Science, Yonsei University, Wonju, Republic of Korea; 2Department of Biomedical Laboratory Science, Korea Nazaren...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kim JS, Kim MW, Kang SJ, Jeong HY, Park SI, Lee YK, Kim HS, Kim KS, Park YS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	EGFR siRNA delivery Anti-EGFR immunonanoparticles Anti-EGFR immunoviroplexes Combinatorial therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/11b5f1edb22d437488a845b0a6ec9473
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11b5f1edb22d437488a845b0a6ec9473
record_format	dspace
spelling	oai:doaj.org-article:11b5f1edb22d437488a845b0a6ec94732021-12-02T02:48:41ZTumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles1178-2013https://doaj.org/article/11b5f1edb22d437488a845b0a6ec94732018-08-01T00:00:00Zhttps://www.dovepress.com/tumor-specific-delivery-of-therapeutic-sirnas--by-anti-egfr-immunonano-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jung Seok Kim,1,* Min Woo Kim,1,* Seong Jae Kang,1,* Hwa Yeon Jeong,1 Sang Il Park,1 Yeon Kyung Lee,1 Hong Sung Kim,2 Keun Sik Kim,3 Yong Serk Park1 1Department of Biomedical Laboratory Science, Yonsei University, Wonju, Republic of Korea; 2Department of Biomedical Laboratory Science, Korea Nazarene University, Cheonan, Republic of Korea; 3Department of Biomedical Laboratory Science, Konyang University, Daejeon, Republic of Korea *These authors contributed equally to this work Background: Efficient target-specific siRNA delivery has always been a primary concern in the field of siRNA clinical application. Purpose: In this study, four different types of anti-epidermal growth factor receptor (EGFR) antibody-conjugated immunonanoparticles were prepared and tested for cancer cell-targeted therapeutic siRNA delivery. Materials and methods: The prepared nanoparticles encapsulating siRNAs were characterized by gel retardation and particle analysis using a Zetasizer. In vitro transfection and reduction of target genes, vimentin and JAK3, were determined using quantitative reverse transcription polymerase chain reaction. In vivo tumor targeting and antitumoral efficacies of the nanoparticles were evaluated in mice carrying tumors. Results: Among these immunonanoparticles, anti-EGFR immunolipoplexes and immunoviroplexes exhibited remarkable cell binding and siRNA delivery to EGFR-expressing tumor cells compared to immunoliposomes and immunovirosomes. Especially, the anti-EGFR immunoviroplexes exhibited the most efficient siRNA transfection to target tumor cells. Therefore, antitumoral vimentin and Janus kinase-3 siRNAs were loaded in the anti-EGFR immunolipoplexes and immunoviroplexes, which were tested in mice carrying SK-OV-3 tumor xenografts. In fact, the therapeutic siRNAs were efficiently delivered to the tumor tissues by both delivery vehicles, resulting in significant inhibition of tumor growth. Moreover, administration of doxorubicin in combination with anti-EGFR immunoviroplexes resulted in remarkable and synergistic tumor growth inhibition. Conclusion: This study provides experimental proof that cancer cell-targeted immunoviroplexes are an efficient siRNA delivery system for cancer therapy. Moreover, this study also suggests that a combination of conventional chemotherapy and tumor-directed anticancer siRNA therapy would be a better modality for cancer treatment. Keywords: EGFR, siRNA delivery, anti-EGFR immunonanoparticles, anti-EGFR immunoviroplexes, combinatorial therapyKim JSKim MWKang SJJeong HYPark SILee YKKim HSKim KSPark YSDove Medical PressarticleEGFRsiRNA deliveryAnti-EGFR immunonanoparticlesAnti-EGFR immunoviroplexesCombinatorial therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 4817-4830 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	EGFR siRNA delivery Anti-EGFR immunonanoparticles Anti-EGFR immunoviroplexes Combinatorial therapy Medicine (General) R5-920
spellingShingle	EGFR siRNA delivery Anti-EGFR immunonanoparticles Anti-EGFR immunoviroplexes Combinatorial therapy Medicine (General) R5-920 Kim JS Kim MW Kang SJ Jeong HY Park SI Lee YK Kim HS Kim KS Park YS Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
description	Jung Seok Kim,1,* Min Woo Kim,1,* Seong Jae Kang,1,* Hwa Yeon Jeong,1 Sang Il Park,1 Yeon Kyung Lee,1 Hong Sung Kim,2 Keun Sik Kim,3 Yong Serk Park1 1Department of Biomedical Laboratory Science, Yonsei University, Wonju, Republic of Korea; 2Department of Biomedical Laboratory Science, Korea Nazarene University, Cheonan, Republic of Korea; 3Department of Biomedical Laboratory Science, Konyang University, Daejeon, Republic of Korea *These authors contributed equally to this work Background: Efficient target-specific siRNA delivery has always been a primary concern in the field of siRNA clinical application. Purpose: In this study, four different types of anti-epidermal growth factor receptor (EGFR) antibody-conjugated immunonanoparticles were prepared and tested for cancer cell-targeted therapeutic siRNA delivery. Materials and methods: The prepared nanoparticles encapsulating siRNAs were characterized by gel retardation and particle analysis using a Zetasizer. In vitro transfection and reduction of target genes, vimentin and JAK3, were determined using quantitative reverse transcription polymerase chain reaction. In vivo tumor targeting and antitumoral efficacies of the nanoparticles were evaluated in mice carrying tumors. Results: Among these immunonanoparticles, anti-EGFR immunolipoplexes and immunoviroplexes exhibited remarkable cell binding and siRNA delivery to EGFR-expressing tumor cells compared to immunoliposomes and immunovirosomes. Especially, the anti-EGFR immunoviroplexes exhibited the most efficient siRNA transfection to target tumor cells. Therefore, antitumoral vimentin and Janus kinase-3 siRNAs were loaded in the anti-EGFR immunolipoplexes and immunoviroplexes, which were tested in mice carrying SK-OV-3 tumor xenografts. In fact, the therapeutic siRNAs were efficiently delivered to the tumor tissues by both delivery vehicles, resulting in significant inhibition of tumor growth. Moreover, administration of doxorubicin in combination with anti-EGFR immunoviroplexes resulted in remarkable and synergistic tumor growth inhibition. Conclusion: This study provides experimental proof that cancer cell-targeted immunoviroplexes are an efficient siRNA delivery system for cancer therapy. Moreover, this study also suggests that a combination of conventional chemotherapy and tumor-directed anticancer siRNA therapy would be a better modality for cancer treatment. Keywords: EGFR, siRNA delivery, anti-EGFR immunonanoparticles, anti-EGFR immunoviroplexes, combinatorial therapy
format	article
author	Kim JS Kim MW Kang SJ Jeong HY Park SI Lee YK Kim HS Kim KS Park YS
author_facet	Kim JS Kim MW Kang SJ Jeong HY Park SI Lee YK Kim HS Kim KS Park YS
author_sort	Kim JS
title	Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
title_short	Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
title_full	Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
title_fullStr	Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
title_full_unstemmed	Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
title_sort	tumor-specific delivery of therapeutic sirnas by anti-egfr immunonanoparticles
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/11b5f1edb22d437488a845b0a6ec9473
work_keys_str_mv	AT kimjs tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT kimmw tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT kangsj tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT jeonghy tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT parksi tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT leeyk tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT kimhs tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT kimks tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles AT parkys tumorspecificdeliveryoftherapeuticsirnasbyantiegfrimmunonanoparticles
_version_	1718402085725143040

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles

Ejemplares similares